Antibodies To Carbamylated Proteins As A Indicators Of Disease In Activity Rheumatoid Arthritis
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by persistent synovitis, progressive joint destruction, and systemic manifestations. Early diagnosis and assessment of disease activity remain essential for preventing irreversible structural damage and improving long-term outcomes. In recent years, antibodies to carbamylated proteins (anti-CarP antibodies) have emerged as promising serological biomarkers in RA. Anti-CarP antibodies are detected in both seropositive and seronegative RA and may precede clinical disease onset. Numerous studies have demonstrated associations between anti-CarP antibodies and disease activity, radiographic progression, bone destruction, and disability. This review summarizes current data regarding the immunopathogenesis, diagnostic value, and clinical significance of anti-CarP antibodies as indicators of disease activity in RA.